Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients.
Cancer vaccines contain tumor antigens in a pro-inflammatory context with the purpose to generate potent antitumor immune responses. However, tumor cells develop different immunosuppressive mechanisms that limit the effectiveness of an anticancer immune response. Therefore, therapeutic vaccine treatment alone is usually not sufficient to generate tumor regression or survival improvement, especially in the advanced disease scenario in which most clinical studies have been conducted. Combining cancer vaccines with different anticancer therapies such as chemotherapy, radiotherapy and other immunotherapeutic agents has had different levels of success. However, the combination of cancer vaccines with different mechanisms of action has not been explored in clinical trials. To address this issue, the current review summarizes the main clinical and immunological results obtained with two different therapeutic vaccines used in advanced non-small-cell lung cancer patients, inducing an immune response against epidermal growth factor (CIMAvax-EGF) and NGcGM3 ganglioside (racotumomab). We also discuss preliminary findings obtained in a trial of combination of these two vaccines and future challenges with these therapies.
Clinical Immunology Department at Clinical Direction, Center of Molecular Immunology, Street 216 Corner 15, PO box 16040, Havana, Cuba, zaima@cim.sld.cu.
Zaima Mazorra
ZM
Herrera
Tania Crombet
TC
Ramos
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; C550107:CIMAvax EGF; D019496:Cancer Vaccines; C000590234:racotumomab